In a new podcast episode, Thomas Hope, MD, shares his insights on glioma imaging and the potential impact of the recently FDA-approved PET agent floretyrosine (18F-FET),
|Slideshows|November 22, 2016
Headache, Seizure, Sensory Changes
Author(s)Harpreet Singh, MD
Case History: 32-year-old patient presented with complaint of headache, seizures, and sensory changes.
Advertisement
Case History: A 32-year-old patient presented with complaint of headache, seizures, and sensory changes.
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
In comparison to the RECIST 1.1 criteria, use of the mpMRI-based NacBI-RADS system for evaluating response to neoadjuvant chemotherapy (NAC) for breast cancer offered an 8 percent higher sensitivity and over 26 percent higher specificity.
Catch up on the most-well viewed radiology content in October 2026.
In a new podcast episode, Manisha Bahl, MD, MPH, FSBI, discusses recently published guidelines on proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
Catch up on the most well-viewed radiology video interviews from Diagnostic Imaging in September 2026.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Issues Breakthrough Therapy Designation for Emerging PSMA PET Agent in Men with Suspected PCa Recurrence
2
Diagnostic Imaging’s Weekly Scan: November 8 — November 14
3
Will PCCT Lead the Next Revolution in Interventional Cardiology?
4
Agfa Radiology to Introduce AI-Powered DR 100s Pro X-Ray Platform at RSNA
5